Franklin Street Advisors Inc. NC Raises Holdings in IDEXX Laboratories, Inc. $IDXX

Franklin Street Advisors Inc. NC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,714 shares of the company’s stock after purchasing an additional 1,583 shares during the period. IDEXX Laboratories comprises 1.4% of Franklin Street Advisors Inc. NC’s investment portfolio, making the stock its 28th biggest position. Franklin Street Advisors Inc. NC’s holdings in IDEXX Laboratories were worth $23,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in IDXX. STF Management LP raised its holdings in IDEXX Laboratories by 1.3% in the second quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after acquiring an additional 16 shares in the last quarter. Clearstead Trust LLC increased its position in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in shares of IDEXX Laboratories by 1.7% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after purchasing an additional 18 shares in the last quarter. Red Spruce Capital LLC lifted its position in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after purchasing an additional 19 shares during the last quarter. Finally, Huntington National Bank grew its stake in shares of IDEXX Laboratories by 0.5% during the second quarter. Huntington National Bank now owns 3,651 shares of the company’s stock worth $1,958,000 after purchasing an additional 19 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $700.34 on Friday. The firm’s fifty day simple moving average is $690.37 and its 200-day simple moving average is $625.57. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock has a market capitalization of $55.92 billion, a price-to-earnings ratio of 55.54, a PEG ratio of 4.16 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $2.80 EPS. IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on IDXX shares. BTIG Research upped their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 29th. Jefferies Financial Group reissued a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Monday. Finally, Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.